Using a Novel Diagnostic Nomogram to Differentiate Malignant from Benign Parathyroid Neoplasms

Area of Science:

• Endocrinology
• Surgical Pathology
• Oncology

Background:

• Distinguishing parathyroid carcinoma (PC) from benign parathyroid neoplasms is diagnostically challenging.
• Histopathological evaluation of PC can be borderline for definitive malignancy.
• Immunohistochemical (IHC) biomarkers are being explored to improve diagnostic accuracy.

Purpose of the Study:

• To develop an IHC tool for diagnosing parathyroid carcinoma (PC).
• To differentiate PC from atypical parathyroid neoplasms and benign adenomas.
• To evaluate the efficacy of specific IHC biomarkers and their combinations.

Main Methods:

• Retrospective analysis of 63 patients with PC, atypical neoplasms, and adenomas (1997-2014).
• Performed IHC analysis for parafibromin, retinoblastoma (RB), PGP9.5, Ki67, galectin-3, and E-cadherin.
• Utilized Receiver Operating Characteristic (ROC) analysis and multivariable logistic regression for biomarker combinations.

Main Results:

• Significant differences in parafibromin, RB, Ki67, PGP9.5, and Galectin-3 expression were observed across diagnostic groups.
• Parafibromin showed the best performance in discriminating PC (AUC 81%).
• A diagnostic nomogram using 5 biomarkers achieved an AUC of 84.9% (optimism-adjusted AUC 80.5%).

Conclusions:

• A diagnostic nomogram combining IHC biomarkers can effectively differentiate parathyroid carcinoma from other parathyroid neoplasms.
• This immunoexpression-based tool has the potential to improve diagnostic classification of parathyroid tumors.
• Further validation of this IHC tool is recommended for clinical application.